Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Gloria Andreossi
Institutions:
Azienda Ospedaliero-Universitaria Careggi,
University of Florence
Observed institutions:
University of Siena,
Azienda Ospedaliero-Universitaria Careggi,
University of Florence
OpenAlex ID:
A5093398779
Response to luspatercept can be predicted and improves overall survival in the real‐life treatment of LR‐MDS
2025
·
Angela Consagra
, Luca Lanino
, et al.
·
HemaSphere
·
14
PDF
IPSS-M risk and specific sex-associated somatic mutations predict response to ESA therapy in LR-MDS: building a new score
2025
·
Marco G. Raddi
, Sophie Park
, et al.
·
Blood
·
5
Improved Overall Survival Among Luspatercept Responders and Predictors of Response
2023
·
Angela Consagra
, Luca Lanino
, et al.
·
Blood
·
2
POSTER: MDS-1116: STAG2-Mutated MDS: Not Only Loss of Function?
2026
·
Gloria Andreossi
, Giorgio Mattiuz
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
MDS-1116: STAG2-Mutated MDS: Not Only Loss of Function?
2026
·
Gloria Andreossi
, Giorgio Mattiuz
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
POSTER: MDS-1103: Elevated Interleukin 1βand Reduced Interleukin 5 in Low-Risk Myelodysplastic Syndromes With Grade 2 or Higher Bone Marrow Fibrosis
2026
·
Maria Stella Martino
, Giorgio Mattiuz
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
MDS-1103: Elevated Interleukin 1βand Reduced Interleukin 5 in Low-Risk Myelodysplastic Syndromes With Grade 2 or Higher Bone Marrow Fibrosis
2026
·
Maria Stella Martino
, Giorgio Mattiuz
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
From chaos to clarity? decoding the inflammatory profiles in lower-risk MDS
2025
·
Sven De Pourcq
, Giorgio Mattiuz
, et al.
·
Blood
Not all that glitters is gold: A simple clinical score to unmask adverse SF3B1WT MDS-RS with low blast count
2025
·
Marco Gabriele Raddi
, Raúl Azibeiro Melchor
, et al.
·
Blood
PDF
ANKRD26-related thrombocytopenia: Hematologic malignancy characteristics, clinical outcomes, and precursor states
2025
·
Lauren Banaszak
, Bianca Barredo
, et al.
·
Blood
PDF
Plenary Session 06: Treatment Low Risk Mds (part 1)
2025
·
Marco Raddi
, Sara Bencini
, et al.
·
Leukemia Research
POSTER: MDS-560 Real-World Outcomes and Predictors of Response and Progression in Lower-Risk Myelodysplastic Syndrome Patients Treated With Luspatercept: A Single-Center Experience
2025
·
Angela Consagra
, Luca Rigodanza
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
POSTER: MDS-693 Distinct Molecular Subtypes in DDX41-Mutated MDS: Germline vs Somatic Landscapes
2025
·
Gloria Andreossi
, Giorgio Mattiuz
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
MDS-560: Real-World Outcomes and Predictors of Response and Progression in Lower-Risk Myelodysplastic Syndrome Patients Treated With Luspatercept: A Single-Center Experience
2025
·
Angela Consagra
, Luca Rigodanza
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
MDS-693: Distinct Molecular Subtypes in DDX41-Mutated MDS: Germline vs Somatic Landscapes
2025
·
Gloria Andreossi
, Giorgio Mattiuz
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
MDS-679 TP53 VAF as an Easier Prognostic Indicator in Myelodysplastic Neoplasms in Comparison With Tp53 Allelic Status
2024
·
Luca Rigodanza
, Gloria Andreossi
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
TP53 VAF as an Easier Prognostic Indicator in Myelodysplastic Neoplasms in Comparison With Tp53 Allelic Status
2024
·
Luca Rigodanza
, Gloria Andreossi
, et al.
·
Clinical Lymphoma Myeloma & Leukemia
Show more works
View as search
Works count:
17
Citation count:
21
H-index:
2
I10-index:
1
Year
Topic
Type
